☆ Ajouter favori
Fiche traitement

CABG

Alexandria University • Maladie coronarienne

Suivi actif À vérifier

Résumé

CABG est développé par Alexandria University. Le traitement est actuellement en À vérifier. Il est associé à Maladie coronarienne. Son objectif thérapeutique principal est À vérifier. Le statut actuel est : suivi actif.

À vérifier

À vérifier
À vérifier
Alexandria University
Egypt
\# WHAT IS THIS STUDY ABOUT? This study compares two different treatment approaches for patients with two heart conditions occurring simultaneously: a narrowed heart valve (aortic stenosis) and narrowed or blocked heart arteries (coronary artery disease). Both conditions are serious and, when they occur together, place considerable strain on the heart. The heart must work harder to pump blood through the narrowed valve while simultaneously receiving an inadequate blood supply through the blocked coronary arteries. \# WHY IS THIS STUDY NEEDED? Until recently, the main treatment option for patients with both conditions was open-heart surgery. This major operation involves opening the chest, temporarily stopping the heart, replacing the heart valve with an artificial valve, and performing coronary artery bypass grafting to restore blood flow around the blocked arteries. Although effective, combined surgery carries significant risks, particularly in older or frailer patients, including prolonged recovery, longer hospital stays (often 2 to 3 weeks), bleeding, kidney injury, and other complications. A newer, less invasive treatment approach is now available. This involves replacing the heart valve through a thin tube (catheter) inserted through a blood vessel in the groin, without opening the chest, and treating the blocked coronary arteries using a fine wire, a small balloon, and a metal mesh tube (stent) placed inside the artery. This approach, known as transcatheter aortic valve implantation (TAVI) combined with percutaneous coronary intervention (PCI), typically requires a shorter hospital stay of approximately 2 to 4 days and may allow an earlier return to normal activities. However, sufficient evidence from well-designed studies is not yet available to establish whether this less invasive approach is as safe and effective as conventional surgery in patients who are not considered at high surgical risk. This study aims to address this evidence gap. \# WHO CAN JOIN THIS STUDY? Adults with severe aortic stenosis and significant coronary artery disease who have been assessed by a specialist heart team as having low or intermediate surgical risk may be eligible to participate. All participants must be considered suitable for both the catheter-based treatment approach and the surgical approach, based on individual coronary anatomy, clinical characteristics, and medical history. Patients with previous coronary artery bypass graft surgery, severely impaired left ventricular systolic function (ejection fraction below 40%), or a recent myocardial infarction within the previous 6 months are not eligible to participate. * WHAT WILL HAPPEN IF A PATIENT JOINS THE STUDY? Participants will receive one of two treatment approaches, selected by a specialist heart team according to individual coronary and valvular anatomy, clinical circumstances, and patient preference: 1. Catheter-based aortic valve replacement combined with coronary artery stenting (TAVI + PCI). 2. Conventional open-heart surgery involving surgical aortic valve replacement and coronary artery bypass grafting (SAVR + CABG). Regardless of the treatment received, all participants will undergo follow-up assessments at hospital discharge, 30 days, 6 months, and 1 year after the procedure. Follow-up will include clinical assessments and appropriate cardiac investigations. * WHAT IS THE STUDY MEASURING? The study will evaluate the incidence of major complications, including all-cause mortality, myocardial infarction, stroke, serious bleeding, and the need for urgent repeat intervention, during the index hospitalization and within 1 year after the procedure. Additional outcomes will include recovery duration, length of hospital stay, and changes in kidney function. * WHERE IS THE STUDY TAKING PLACE? The study is being conducted at Alexandria University Hospitals and other major cardiac centres across Egypt, with a planned total enrolment of 100 participants. \# WHO IS CONDUCTING THE STUDY? The study is being conducted by Dr. Moustafa AbdelMohsen Elsayed Madkour, Department of Cardiology and Angiology, Faculty of Medicine, Alexandria University, Egypt, under the supervision of Prof. Dr. Mohamed Ahmed Sobhy and Prof. Dr. Tarek Hussien Elzawawy.
2026-11-05

Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique

À vérifier
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé

Objectif scientifique de l’étude

classification automatique vérifiable
À vérifier Confiance automatique : 0%

Description affichée depuis l’essai compatible NCT07926022, afin d’éviter le mélange entre plusieurs indications d’une même molécule.

Contrôle de cohérence : 85/100

L’objectif est absent ou classé « Autre » et doit être recalculé à partir du protocole.

Transparence et qualité de la fiche

données vérifiables
ClassificationÀ vérifier
Confiance de la fiche85 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-11-05
Anomalies détectées1
Validation humaineValidation humaine non effectuée
Donnée issue d’une source Donnée normalisée automatiquement Interprétation algorithmique

Classification scientifique multi-axes

ne pas confondre statut et résultat
État de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable

Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.

Indicateurs factuels

sans score subjectif
Phase enregistréeÀ vérifier
Études associées12
Publications associées3
Statut consolidéSuivi actif

Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.

Historique factuel de la molécule

40 événement(s) daté(s)

Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.

DateÉvénementSource
2024-10-10Début de l’étudeNCT06326996Registre d’essai clinique
2024-12-05Début de l’étudeNCT07891299Registre d’essai clinique
2026-02-01Début de l’étudeNCT07926022Registre d’essai clinique
2026-02-01Début de l’étudeNCT07472959Registre d’essai clinique
2026-02-07Début de l’étudeNCT07823400Registre d’essai clinique
2026-02-11Début de l’étudeNCT07875049Registre d’essai clinique
2026-03-02Fin de l’étude prévue / enregistréeNCT07891299Registre d’essai clinique
2026-07-12PublicationImmunomodulatory Effects of Volatile Anesthetic Sevoflurane on Cardiomyocytes after Coronary Artery Bypass Grafting: Insights from Bioinformatics Analysis.Iranian journal of allergy, asthma, and immunology
2026-08-13PublicationComparative Effects of Different Statin Regimens on Postoperative Outcomes in Isolated Coronary Artery Bypass Grafting: A Propensity Score-Matched Analysis.Journal of clinical medicine
2026-08-16PublicationLong-term safety and effectiveness of hybrid coronary revascularization compared to conventional revascularization strategies: a systematic review and meta-analysis.Annals of medicine and surgery (2012)
2026-09-11Fin de l’étude prévue / enregistréeNCT07472959Registre d’essai clinique
2026-09-17Début de l’étudeNCT07877532Registre d’essai clinique
2026-09-30Début de l’étudeNCT07795398Registre d’essai clinique
2026-09-30Début de l’étudeNCT07872982Registre d’essai clinique
2026-10-18Création de l’enregistrementNCT07795398Registre d’essai clinique
2026-10-18Création de l’enregistrementNCT07872982Registre d’essai clinique
2026-10-18Création de l’enregistrementNCT07875049Registre d’essai clinique
2026-10-18Création de l’enregistrementNCT07877532Registre d’essai clinique
2026-10-18Création de l’enregistrementNCT07823400Registre d’essai clinique
2026-10-25Création de l’enregistrementNCT07892976Registre d’essai clinique
2026-10-25Création de l’enregistrementNCT07891299Registre d’essai clinique
2026-10-30Fin de l’étude prévue / enregistréeNCT07823400Registre d’essai clinique
2026-11-01Début de l’étudeNCT07912801Registre d’essai clinique
2026-11-05Dernière mise à jour des donnéesCABGBiomedical Watch
2026-11-08Création de l’enregistrementNCT07918781Registre d’essai clinique
2026-11-08Création de l’enregistrementNCT06326996Registre d’essai clinique
2026-11-08Création de l’enregistrementNCT07472959Registre d’essai clinique
2026-11-08Création de l’enregistrementNCT07912801Registre d’essai clinique
2026-11-09Création de l’enregistrementNCT07926022Registre d’essai clinique
2026-12-01Début de l’étudeNCT07918781Registre d’essai clinique
2026-12-20Fin de l’étude prévue / enregistréeNCT07875049Registre d’essai clinique
2027-01-01Début de l’étudeNCT07892976Registre d’essai clinique
2027-06-01Fin de l’étude prévue / enregistréeNCT07926022Registre d’essai clinique
2027-07-30Fin de l’étude prévue / enregistréeNCT07877532Registre d’essai clinique
2027-09-30Fin de l’étude prévue / enregistréeNCT06326996Registre d’essai clinique
2027-12-01Fin de l’étude prévue / enregistréeNCT07912801Registre d’essai clinique
2027-12-30Fin de l’étude prévue / enregistréeNCT07872982Registre d’essai clinique
2029-10-01Fin de l’étude prévue / enregistréeNCT07795398Registre d’essai clinique
2030-12-31Fin de l’étude prévue / enregistréeNCT07918781Registre d’essai clinique
2044-01-01Fin de l’étude prévue / enregistréeNCT07892976Registre d’essai clinique

Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés

12 essai(s)
NCT Titre Phase Statut administratif Pays Sponsor
NCT07926022 TAVI and PCI in Comparison to SAVR and CABG in Low and Intermediate Risk Patients With Severe Aortic Stenosis À vérifier RECRUITING Egypt Alexandria University
NCT07918781 CALM — Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG Non applicable NOT_YET_RECRUITING China China National Center for Cardiovascular Diseases
NCT06326996 B1&CABG — Thiamine Intervention and Coronary Artery Bypass Grafting Phase 1 RECRUITING United States University of California, Los Angeles
NCT07472959 Effect of Intraoperative Morphine on Postoperative Pain After CABG Phase 4 COMPLETED Turkey (Türkiye) Istanbul University - Cerrahpasa
NCT07912801 Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery Phase 4 NOT_YET_RECRUITING China Peking University First Hospital
NCT07892976 The CORE Platform Trial Non applicable NOT_YET_RECRUITING Belgium, Denmark, Netherlands Copenhagen Trial Unit, Center for Clinical Intervention Research
NCT07891299 VR-CABG — VR During Chest Tube Removal After CABG Non applicable COMPLETED Turkey (Türkiye) Maltepe University
NCT07795398 DAN-RELEASE - Reconsidering Long-Term Aspirin in the Elderly Patients With Stable Ischemic Heart Disease Phase 4 RECRUITING Denmark Odense University Hospital
NCT07872982 BrainProtect-guided, Real-time Cerebral Autoregulation Monitoring and Protection of Brain During Cardiac Surgery With Cardiopulmonary Bypass Requiring Heart-lung Machine Non applicable NOT_YET_RECRUITING United States, Austria, Italy, Lithuania Scienceforbrain, UAB
NCT07875049 Additional Effects of Flutter With Conventional Chest Physiotherapy on Peak Expiratory Flow Rate and Chest Expansion in Post CABG Patients With COPD Non applicable RECRUITING Pakistan Foundation University Islamabad
NCT07877532 Serratus Anterior Plane Block for Recovery After Minimally Invasive CABG Non applicable NOT_YET_RECRUITING Non communiqué Chinese PLA General Hospital
NCT07823400 MIECC-CABG — MIECC vs Conventional Cardiopulmonary Bypass and Systemic Inflammation in CABG À vérifier ACTIVE_NOT_RECRUITING Turkey (Türkiye) Bursa Yuksek Ihtisas Training and Research Hospital

Publications liées

3 publication(s)

Publications liées

3 publication(s)
Titre PMID DOI Journal Date
Long-term safety and effectiveness of hybrid coronary revascularization compared to conventional revascularization strategies: a systematic review and meta-analysis. Voir source 41675882 10.1097/MS9.0000000000004561 Annals of medicine and surgery (2012)
Comparative Effects of Different Statin Regimens on Postoperative Outcomes in Isolated Coronary Artery Bypass Grafting: A Propensity Score-Matched Analysis. Voir source 42590161 10.3390/jcm15156060 Journal of clinical medicine
Immunomodulatory Effects of Volatile Anesthetic Sevoflurane on Cardiomyocytes after Coronary Artery Bypass Grafting: Insights from Bioinformatics Analysis. Voir source 42437319 Iranian journal of allergy, asthma, and immunology

Sources officielles

liens de recherche

Dernière mise à jour des données : 2026-11-05

Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.